Scope is fixed at Product × Technology × Application × Channel × Region, covering seven regions and thirty countries across prescription drugs, generics, branded formulations, injectables, OTC lines, biologics, and specialty therapies. Units for value and volume, along with the currency basis, are defined upfront to maintain consistency across dosage forms and regulatory classes. Monthly signals inform our quarterly baselines, and forecasts run at constant FX unless scenario analysis requires adjustments for regulatory or batch-release events.
We count shipments once at vendor-to-channel dispatch, ensuring that batch-level transfers, contract manufacturing flows, and API-to-formulation transfers are not double-counted. Subsidiary inventory is excluded until it enters the commercial channel. Re-exports are reassigned to the country of final use when determinable, which matters for tender-linked products and parallel-trade corridors. Manufacturer self-consumption and bona-fide public-health donations are captured to protect installed-base integrity for therapeutic volumes and dosage availability.
ASP is captured at the distributor level, including freight, insurance, and import duties within vendor or channel pricing. POS taxes are excluded. Outliers are normalized. Prices are weighted across international, domestic, and China-based vendors to reflect market mixes for APIs, formulations, injectables, and OTC lines. For bulk chemicals and intermediates, bulk distributor prices are used.
Brand share is calculated as Brand Value ÷ Category Value by geography and channel. In the absence of EPOS data, we triangulate brand value using filings, tender bulletins, procurement disclosures, and public multi-signal proxies (SRAP, PII, RHI), calibrated to disclosed anchors and bounded by corridor tests that reflect formulation prices, therapy-class substitution, and supply constraints.
At FMI, trade flows are compiled using HS codes relevant to APIs, intermediates, formulations, dosage forms, and biologics. Mirror-stat checks detect gaps. Adjustments are made for re-exports via known pharmaceutical hubs, valuation differences between FOB and CIF, and reclassification events affecting APIs, excipients, and finished-dose medicines. Series are time-aligned and currency-normalized. Apparent consumption closes as Production + Imports − Exports ± Stock Change, factoring in safety stocks common in GMP and regulated distribution.
Revenue and volume are allocated across direct supply to hospitals, distributor/wholesale routes, retail/mass outlets, pharmacy/specialty channels, e-commerce for OTC products, and tender/government pathways. We model margin stacks for each channel, reflecting pharmacy markups, wholesale terms, and tender-driven pricing. Leakage through grey or parallel pharmaceutical trade is estimated using guardrails and anomaly detection on pricing, stock availability, and regional turnover.
We map pharmaceutical supply chains from input to end-use, covering API production, formulation plants, cold-chain segments, packaging, distribution nodes, and final dispensing points. Diagnostics cover capacity, utilization, lead times, batch-release delays, yield loss, scrap, lane reliability, and inventory policies across GMP environments. Concentration indices and single points of failure, particularly in APIs, excipients, vial/ampoule supply, and sterile fill-finish capacity, are stress-tested under demand shocks or supply disruptions. Supplier scorecards track quality, on-time delivery, cost variance, and regulatory-risk metrics.
Method 1: Regression-based models draw predictors from production volumes, utilization patterns, trade flows in APIs and formulations, capex in pharma plants, regulatory approvals, and price corridors. We apply stability tests, residual diagnostics, structural-break handling, and backtesting to validate the model under regulatory and tender-driven variability.
Method 2: Driver growth-rate models apply weighted growth to audited baselines, using drivers such as therapy-class adoption, formulary inclusion, reimbursement changes, and manufacturing throughput. We tune weights to realized outcomes and apply revisions when drivers rebase or when shocks impact demand, regulatory decisions, or plant output.
Triangulation includes Product Category Analysis, n-per-Population intensity for therapy penetration, and Economic Envelope guardrails to ensure scenarios remain feasible under healthcare budgets, procurement cycles, and pricing controls. Outputs include value, volume, installed base, and price scenarios with confidence bands.
Regression accuracy is monitored via MAPE with diagnostic checks and stability tests. Growth-rate models are validated through correlation checks and backtests, with tolerance bands tuned to volatility in pharmaceutical categories, regulatory timing, tender cycles, and substitution effects. Reconciliation ensures closure of apparent consumption, and we test price corridors along with FX and manufacturing capacity constraints. A dual-analyst review is required, and change logs capture the rationale for each adjustment.
Value = Units × ASP; Installed Base = Σ Shipments − Retirements; Apparent Capacity = Production / Capacity Factor; Brand Share = Brand Value ÷ Category Value; Channel Mix = Channel Revenue ÷ Total; Export–Import Balance = Exports − Imports.
UN Comtrade/ITC Trade Map; Eurostat/PRODCOM; US Census/BEA/BLS; OECD; IEA/EIA/USGS/UNCTADstat; FAOSTAT/USDA; FDA/EMA/PMDA/CDSCO; ClinicalTrials.gov/WHO ICTRP; OICA/ACEA/SIAM; EDGAR/SEMI/GSMA/3GPP; EU TED/SAM.gov; public retail signals (filings, store locators, circulars, app stores, public social). Lineage cards display pull dates, access type, transforms, confidence tier, and caveats.
Quarterly baselines with monthly micro-updates for high-frequency shifts; rapid shock notes for policy/outage/recall/price spikes. Deliverables include executive memo, workbook/models, 16:9 dashboards with lineage, and a change log. Optional: weekly SRAP/PII/RHI tiles for retail.
Methodology
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
